Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Immunodiagnostic Sys (IDH)

  Print      Mail a friend

Friday 21 April, 2017

Immunodiagnostic Sys

Trading Update

RNS Number : 9207C
Immunodiagnostic Systems Hldgs PLC
21 April 2017




Trading Update


Immunodiagnostic Systems Holdings PLC 

21 April 2017


Immunodiagnostic Systems Holdings plc

Trading Update for the year ended 31 March 2017

Immunodiagnostic Systems Holdings PLC ("the Group"), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, today provides a trading update for the financial year ended 31 March 2017.


Total Group revenue is expected to be approximately £40m, an increase of around 4% compared to the previous year.  This reported revenue number has been favorably impacted by the weakening of the pound against the Euro and US Dollar. At constant exchange rates ("CER") the revenue decreased by around 8%.   There were no changes in scope during the last financial year, thus these numbers are like for like.


Automated Business

Revenues in our automated CLIA business are expected to be approximately £21.4m, approximately 3% higher than the prior year at CER. 


·      Automated 25OH Vitamin D revenue of approximately £6.8m represents a decline of around 17% at CER compared to the prior year.   While this business continues to decline, the rate of decline is lower than we have seen in previous years.   This decrease is mainly a result of our main laboratory customers continuing to transfer this assay to workhorse analysers after termination of their contractual obligations with the Group.

·      Automated specialty business (automated business excluding 25OH Vitamin D) revenue of approximately £13.3m represents a growth of around 16% at CER compared to the prior year.  This growth was generated by multiple products, and hence the business is developing a more diversified product base, which should lay the foundations for future growth.


During the year we were pleased to launch four new CLIA automated assays for the IDS iSYS analyser.  This brings the total assay menu with a CE-mark up to nineteen assays, and represents a 25% expansion of the assay menu during the year. The rate of four new CE-marked product launches is up from one in the previous financial year, but we missed our internal goal of six new launches.


In the USA we were able to get clearance for one new assay, bringing the number of assays up to ten.  In China the number of CFDA-cleared assays stayed unchanged at four.


Annual gross placements of analyzers in markets with direct sales organizations were 40 (Prior Year: 31).  Just as importantly, we were able to reduce the number of returns to 24 (Prior year: 43).  Thus net placements after returns - the core KPI signaling our potential for resumed growth - stood at 16 (Prior Year: minus 12).


Another KPI we are monitoring is the average number of assays run on an iSYS analyzer as a larger number increases our revenues per instrument and increases customer retention.  This KPI increased from 3.9 to 4.3 over the year, reflecting the ability of our sales organization for upselling.  


We believe the positive progression of the KPIs outlined above reflects the progress made during the course of the year. Our roadmaps for R&D, sales and marketing are clearly outlined and our management team is working on getting better on the respective processes each month. We are therefore optimistic that this progress will continue into the next year.


Manual Business

Manual assay revenues are expected to be approximately £12.7m, 11% lower at CER than the prior year.  The majority of the decline is caused by lower 25OH Vitamin D revenues - which declined by around 36% at CER.  Revenue in the remainder of the business declined by around 4% at CER. 


During the year our actions taken to stem the decline resulted in a slowdown in the downward trend.  During the coming year we aim to place more emphasis on building the sales processes and distribution channels related to our manual business. Our goal is to halt the decline at CER.


Licensing and Technology Business

Licensing and Technology revenues are expected to be approximately £5.9m, a decline of around 30% at CER compared to the prior year.   Within this business, royalty income - based on monetizing our know-how and IP in biologics - is expected to be £2.8m, equating to a 53% decline at CER.   However income from technology partners - based on monetizing our instrument technology - increased to £3.1m, which is a 23% increase at CER.   Royalty income is accrued based on preliminary estimates provided by our customers, and is thus subject to revision.  We do not expect to see significant royalty income during the next financial year, thus expect to see a continued decline in the license and technology revenues in the next year, in accordance with guidance provided by the Group since June 2016.   


As of 31 March 2017 the Group employed 275 people on a full time employment basis (31 March 2016:  315).  


Closing cash and cash equivalents are expected to be around £31.5m (31 March 2016: £26.6m).


The management team is encouraged by these results, which are above our expectations for the year.  They reflect the hard work which has been undertaken to stabilize the performance of the Group after deteriorating financial and operational performance in previous years. We would therefore like to thank all our staff for the extraordinary effort they put in to effect this turn-around.


Preliminary results for the year ended 31 March 2017 will be announced on 21 June 2017.


This announcement includes inside information.


For further information:


Immunodiagnostic Systems Holdings plc                         Tel : +44 (0)191 5190660

Regis Duval, Chief Executive Officer

Paul Martin, Group Finance Director


Peel Hunt LLP                                                                                    Tel : +44 (0)207 418 8900

James Steel

Oliver Jackson 

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t